Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Cogent Biosciences, a biotechnology firm, announced that Andrew Robbins, CEO, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. This virtual event will occur from February 14-18, 2022, with Robbins' chat streaming live on February 16 at 10:00 a.m. ET. A recording will be available for 90 days post-event. Cogent Biosciences focuses on precision therapies for genetically defined diseases, notably its drug bezuclastinib, targeting mutations associated with systemic mastocytosis and gastrointestinal stromal tumors.

CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, will participate in a fireside chat during the 11^th Annual SVB Leerink Global Healthcare Conference, taking place virtually February 14 – 18, 2022.

The fireside chat will stream live Wednesday, February 16 at 10:00 a.m. ET, after which a recording will be available to conference attendees for 90 days. Links to the webcast and recording registration page can be found under the “Events” tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

Media contact:
Amanda Sellers
asellers@vergescientific.com
301.332.5574

FAQ

When will Andrew Robbins speak at the SVB Leerink Global Healthcare Conference?

Andrew Robbins will participate in a fireside chat on February 16, 2022, at 10:00 a.m. ET.

How can I watch the fireside chat with Andrew Robbins?

The chat will stream live on the Cogent Biosciences website and will be available for 90 days after the event.

What is bezuclastinib developed by Cogent Biosciences?

Bezuclastinib is a selective tyrosine kinase inhibitor designed to target the KIT D816V mutation and other KIT mutations related to systemic mastocytosis and advanced gastrointestinal stromal tumors.

What is the focus of Cogent Biosciences?

Cogent Biosciences is focused on developing precision therapies for genetically defined diseases.

Where is Cogent Biosciences located?

Cogent Biosciences is based in Cambridge, Massachusetts, and Boulder, Colorado.